BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Vaxon-Biotech Announces Phase I Study Results for VX-001 Immunotherapy in Cancer Patients

EVRY-GENOPOLE®, 6th December 2004 – Vaxon-Biotech today announces that it has completed the phase I trial of its candidate vaccine VX-001. The trial was conducted at Heraklion University Hospital in Greece. VX-001 was well-tolerated, stimulated T-cell immunity, and continues to show clinical benefits in participating patients. Open PDF file to view the full Press Release.
 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.